New Drug Dossier

Click here to subscribe

MM&M's New Drug Dossier combines promotional insights with clinical information to offer marketers the first complete online resource for newly approved drugs. 

Webcast

Entry kit available online February 11

The time is almost here to enter the industry's most distinguished awards program. MM&M Awards honor exceptional creativity and marketing effectiveness in healthcare. With a wide range of categories, you're sure to find the perfect fit to showcase your best work. Visit www.mmm-online.com/awards for more information and to download your entry kit.      

Subscribe Today


MM&M offers the most relevant news, analysis, opinion, feature stories and special reports to nearly 15,000 marketing executives at pharma companies, agencies and in healthcare media. Click here to subscribe.

MM&M Career & Salary Survey Premium Edition

Are you making as much as your peers?

Complete the MM&M Career & Salary Survey 2008 now for a chance to win the latest Nintendo console. All responses will remain confidential. Click here to take the survey. 

 

The MM&M News Brief provides news and features delivered direct to your inbox. To access the full text, simply click the headline.

Latest News

Brisk uptake for Lyrica as ad campaign evolves

If unbranded direct-to-consumer ads in support of Pfizer's Lyrica for fibromyalgia moved the needle on prescriptions, branded creative could boost uptake even more.
 

Marketer takes helm of Sanofi vaccines division

Sanofi Pasteur named Wayne Pisano president and CEO, replacing David Williams, who is retiring. He reports to Sanofi Aventis CEO Gerard Le Fur.
 

Sepracor in licensing pact for anti-epileptic compound

Sepracor has entered a licensing deal with Bial for the development and commercialization of Bial's anti-epileptic compound BIA 2-093 in the US and Canada.
 

Bolling assumes head of trade group formed from three others

Whether client or service-side, student or seasoned pro, one national trade group wants to to serve all of your educational needs.
 

AstraZeneca seeks new Seroquel XR indications

AstraZeneca said it plans to seek FDA approval to sell an extended release version of its Seroquel XR schizophrenia drug to treat both manic and depressive episodes associated with bipolar disorder.
 

In Brief

Product news

Sciele Pharma said the FDA has approved all four dosage strengths of the new Sular formulation, which utilizes SkyePharma's patented Geomatrix technology and provides a lower dose of Sular for each of its current doses.
 

People news

Kimberly Ray has joined Eisai as senior manager, pharmacoepidemiology and risk management in medical services.
 

Company news

Merck and Addex Pharmaceuticals entered a deal to develop a drug candidate for schizophrenia, under which Merck will pay Addex up to $702 million in cash plus royalties.
 

Latest Features

MM&M All-Stars Company of the Year: Merck

When the going got tough, Merck got back to basics.
 

MM&M All-Stars Large Pharma Marketing Team of the Year: Cymbalta (Eli Lilly)

Eli Lilly & Co. spent $128 million promoting Cymbalta (duloxetene) for the year through August, according to IMS Health.
 

MM&M All-Stars Small Pharma Marketing Team of the Year: Keppra (UCB, Inc.)

Since last year, when UCB, Inc. let users of its antiepileptic Keppra speak for the brand, patients have become an important visual and vocal component in all promotion.
 

MM&M All-Stars Agency of the Year: AbelsonTaylor

Uncommonly good creative has helped standalone agency AbelsonTaylor stand out among its peers, garner acclaim and earn loyalty from clients.
 

MM&M All-Stars Media Brand of the Year: Sermo

On September 20, 2007, Sermo's founder and CEO Dr. Daniel Palestrant stepped up to the podium at the Health 2.0 conference in San Francisco and in less than three minutes summarized how his brainchild, an online community for physicians launched just a year earlier, has forever changed the healthcare media landscape.
 

Beyond the Patent: Extending the Life of Brands

With many of the industry's major blockbuster drugs coming off-patent in the next few years, pharmaceutical companies are scrambling to extend the life of their biggest brands. Larry Friedman, PhD, offers some potential solutions based on brand architecture and flow of brand equity
 



Advertise
For details on how to advertise in MM&M News Brief, please email Doreen Gates

Unsubscribe
To unsubscribe from the MM&M News Brief click here.
To manage your entire MM&M profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All MM&M newsletters are sent from the domain "email.mmm-online.com". When configuring e-mail or spam
filter rules, please use this domain name.

Medical Marketing & Media Magazine
114 W. 26th Street 4th Floor
New York N.Y. 10001
Phone: (646) 638-6000
Fax: (646) 638-6150
http://www.mmm-online.com/

© 2013 Haymarket Media Inc.